After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral

Why It Matters

The downward sales trend threatens Sarepta’s cash flow and its ability to fund costly gene‑therapy development, while leadership turnover may amplify market volatility. Restoring confidence in Elevidys is critical for the broader DMD treatment landscape and for investors betting on high‑price, one‑time therapies.

Key Takeaways

• Elevidys Q4 sales fell to $110 million.
• FY 2025 sales dropped below $900 million.
• Analysts project 2026 sales under $500 million.
• 2025 safety events damaged gene‑therapy reputation.
• CEO Doug Ingram will exit by year‑end.

Pulse Analysis

Elevidys, Sarepta Therapeutics’ once‑launched gene therapy for Duchenne muscular dystrophy, has entered a precarious phase. After peaking near $1 billion in annual revenue, the product recorded only $110 million in fourth‑quarter sales, pulling full‑year net sales to $898.7 million. The decline is not merely seasonal; analysts now forecast 2026 revenues slipping below the $500 million threshold that management has long cited as a floor. This contraction reflects both a muted market response to recent safety concerns and a broader hesitation among payers to fund high‑cost, single‑dose therapies without clear long‑term benefit data.

The safety setbacks of 2025, which included multiple deaths linked to the adeno‑associated virus vector, have reshaped stakeholder confidence across the gene‑therapy sector. Regulators are scrutinizing Elevidys more closely, prompting Sarepta to schedule a pivotal FDA meeting to discuss the future of its exon‑skipping portfolio. Converting the existing accelerated approval to a traditional one could restore some credibility, but the agency will likely demand robust post‑marketing evidence, especially regarding liver toxicity mitigated by sirolimus. Consequently, the company must balance ongoing data generation with heightened compliance costs and potential label restrictions.

Amid the sales slump, Sarepta is betting on pipeline diversification and leadership renewal to revive growth. Upcoming data from the Arrowhead partnership targeting myotonic dystrophy and from its FSHD candidate could unlock a combined $1 billion market opportunity, while non‑ambulatory Elevidys results may broaden the therapy’s indication set. The announced CEO transition, with Doug Ingram’s departure slated for year‑end, adds a layer of uncertainty but also opens the door for a successor who can steer a more aggressive commercial and educational campaign. Investors will watch closely for signs of a H2 2026 sales rebound and a stabilized share price.